CN111818941A - 抗转化生长因子β的自然杀伤细胞 - Google Patents

抗转化生长因子β的自然杀伤细胞 Download PDF

Info

Publication number
CN111818941A
CN111818941A CN201980016864.3A CN201980016864A CN111818941A CN 111818941 A CN111818941 A CN 111818941A CN 201980016864 A CN201980016864 A CN 201980016864A CN 111818941 A CN111818941 A CN 111818941A
Authority
CN
China
Prior art keywords
cells
cell
tgf
beta
tgfβi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980016864.3A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·李
J·A·福尔茨·斯特林费洛
J·爱德华兹·莫斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nationwide Childrens Hospital Inc
Original Assignee
Nationwide Childrens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nationwide Childrens Hospital Inc filed Critical Nationwide Childrens Hospital Inc
Publication of CN111818941A publication Critical patent/CN111818941A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980016864.3A 2018-01-30 2019-01-29 抗转化生长因子β的自然杀伤细胞 Pending CN111818941A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623682P 2018-01-30 2018-01-30
US62/623,682 2018-01-30
PCT/US2019/015617 WO2019152387A1 (en) 2018-01-30 2019-01-29 Transforming growth factor beta-resistant natural killer cells

Publications (1)

Publication Number Publication Date
CN111818941A true CN111818941A (zh) 2020-10-23

Family

ID=67478491

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980016864.3A Pending CN111818941A (zh) 2018-01-30 2019-01-29 抗转化生长因子β的自然杀伤细胞

Country Status (12)

Country Link
US (1) US20200368281A1 (https=)
EP (1) EP3746118A4 (https=)
JP (2) JP7591406B2 (https=)
KR (2) KR20250093419A (https=)
CN (1) CN111818941A (https=)
AU (1) AU2019213678B2 (https=)
BR (1) BR112020015490A2 (https=)
CA (1) CA3090096A1 (https=)
IL (2) IL276374B2 (https=)
MX (1) MX2020008044A (https=)
SG (1) SG11202007288VA (https=)
WO (1) WO2019152387A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023517220A (ja) * 2020-03-11 2023-04-24 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 微生物感染症の治療のためのｎｋ細胞およびそれらの使用
AU2021263579A1 (en) * 2020-04-30 2022-12-01 Research Institute At Nationwide Children's Hospital Overcoming immune suppression with TGF-β resistant NK cells
KR20250154429A (ko) * 2023-03-02 2025-10-28 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 암 면역요법을 위한 형질전환 성장인자-베타 슈퍼패밀리가 각인된 자연살해세포

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143441A (zh) * 2014-01-13 2015-12-09 深圳市汉科生物工程有限公司 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法
US20170056448A1 (en) * 2015-09-01 2017-03-02 Ifm Therapeutics, Inc Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2058388A1 (en) * 2007-10-05 2009-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Non-conventional NKT cells for use in cancer therapy
EP3223856B1 (en) 2014-10-27 2025-09-24 University of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
WO2017048809A1 (en) * 2015-09-14 2017-03-23 Regents Of The University Of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143441A (zh) * 2014-01-13 2015-12-09 深圳市汉科生物工程有限公司 用带有活性因子的细胞空壳作为淋巴细胞体外培养增效剂的制备及其应用方法
US20170056448A1 (en) * 2015-09-01 2017-03-02 Ifm Therapeutics, Inc Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FOLASHADE OTEGBEYE ET AL: "Inhibiting TGF-Beta Signaling in the Tumor Micro-Environment Enhances the Cytotoxic Function of Adoptive NK Cells", 703. ADOPTIVE IMMUNOTHERAPY: POSTER I, vol. 22, no. 128, 2 December 2016 (2016-12-02) *
MING O. LI ET AL: "Transforming growth factor-beta regulation of immune responses", 《ANNU. REV. IMMUNOL.》, no. 24, pages 99 - 146, XP008082309, DOI: 10.1146/annurev.immunol.24.021605.090737 *
YU ET AL: "Pro-and anti-inflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells", 《IMMUNITY》, no. 24, pages 575 *

Also Published As

Publication number Publication date
AU2019213678A1 (en) 2020-09-03
AU2019213678B2 (en) 2025-06-26
JP7591406B2 (ja) 2024-11-28
EP3746118A4 (en) 2021-11-24
US20200368281A1 (en) 2020-11-26
KR20250093419A (ko) 2025-06-24
IL309656A (en) 2024-02-01
EP3746118A1 (en) 2020-12-09
IL276374B1 (en) 2024-01-01
IL276374A (en) 2020-09-30
RU2020127722A (ru) 2022-02-28
MX2020008044A (es) 2020-12-10
KR20200118449A (ko) 2020-10-15
IL276374B2 (en) 2024-05-01
JP2025026937A (ja) 2025-02-26
CA3090096A1 (en) 2019-08-08
SG11202007288VA (en) 2020-08-28
KR102822300B1 (ko) 2025-06-17
WO2019152387A1 (en) 2019-08-08
BR112020015490A2 (pt) 2021-03-23
JP2021512164A (ja) 2021-05-13

Similar Documents

Publication Publication Date Title
JP6920644B2 (ja) 幹細胞の免疫制御作用を調節する方法
Morris et al. Advances in the understanding of acute graft‐versus‐host disease
Lo et al. Leptin signaling protects NK cells from apoptosis during development in mouse bone marrow
Yang et al. Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy
JP2025026937A (ja) トランスフォーミング増殖因子ベータ抵抗性ナチュラルキラー細胞
Wu et al. Essential role of interleukin-12/23p40 in the development of graft-versus-host disease in mice
Cifù et al. The exposure to osteoarthritic synovial fluid enhances the immunomodulatory profile of adipose mesenchymal stem cell secretome
US20240398695A1 (en) Methods of T Cell Expansion and Activation
EP3834849A1 (en) Method for treating tumor using immune effector cell
JP7681908B2 (ja) Ｃｃｒ２＋造血幹細胞は養子細胞療法におけるｔ細胞活性化を媒介する
US20240228964A9 (en) Highly Potent M-CENK Cells And Methods
JP6334810B2 (ja) Ｉｆｎを用いた非接着培養による樹状細胞の調製方法
Libregts et al. Parallels between immune driven-hematopoiesis and T cell activation: 3 signals that relay inflammatory stress to the bone marrow
US20220249567A1 (en) Low density cell culture
RU2830178C2 (ru) Естественные клетки-киллеры, резистентные к трансформирующему ростовому фактору бета
US20230131219A1 (en) Use of agonists to augment car t function in solid tumors
CN112399858A (zh) 医学用途
CN112779216B (zh) 体外扩增和活化自然杀伤细胞的方法及其药物组合物
CA3017603C (en) Methods of t cell expansion and activation
EP4724570A1 (en) Small molecule based method of modifying t cells
Li et al. Effect of thymosin α1 on the phenotypic and functional maturation of dendritic cells from children with acute lymphoblastic leukemia
HK40047175A (en) Medical uses
Wurzenberger Dendritic cell vaccines in tumor immunotherapy: Immune activation strategies with ligands for the Toll-like receptors 7 and 9
Gilmore et al. Differential CD34+ engraftment of nod-scid mice with ex vivo expanded human CD34+ cord blood stem cells correlates with CD38 phenotype
Bernink The biology of human innate lymphoid cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination